1. Home
  2. SMID vs PLYX Comparison

SMID vs PLYX Comparison

Compare SMID & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

SELL

Current Price

$24.68

Market Cap

117.7M

Sector

Industrials

ML Signal

SELL

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

HOLD

Current Price

$1.80

Market Cap

112.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
PLYX
Founded
1960
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.7M
112.7M
IPO Year
1996
2025

Fundamental Metrics

Financial Performance
Metric
SMID
PLYX
Price
$24.68
$1.80
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.50
AVG Volume (30 Days)
6.7K
★ 23.5K
Earning Date
11-16-2026
11-14-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
★ 77.53
EPS
★ 0.51
N/A
Revenue
★ $93,446,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$46.96
★ N/A
Revenue Growth
★ 19.03
N/A
52 Week Low
$20.89
$1.69
52 Week High
$40.00
$10.93

Technical Indicators

Market Signals
Indicator
SMID
PLYX
Relative Strength Index (RSI) 61.71 31.43
Support Level $23.51 N/A
Resistance Level $25.25 $2.18
Average True Range (ATR) 0.66 0.11
MACD 0.36 -0.02
Stochastic Oscillator 88.96 11.74

Price Performance

Historical Comparison
SMID
PLYX

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: